The promise of a simple blood test to detect cancer early, sidestepping invasive and costly biopsies, has been a long-standing grail in oncology. For a small team of scientists in Bratislava, that promise now hinges on a subtle, often overlooked biological the sugar molecules, or glycans, that coat our proteins. Glycanostics, founded in 2017, is betting that analyzing these glycan patterns on common biomarkers like PSA can yield a more accurate, non-invasive window into early-stage tumors than genetics or proteins alone. Their first commercial target is prostate cancer, a disease where the standard PSA test is notoriously unreliable, leading to millions of unnecessary biopsies every year.
A scientific wedge in a crowded field
Glycanostics’s differentiation lies not in discovering new biomarkers, but in reading a new layer of information from existing ones. The company’s core technology is a magnetic bead-based ELISA assay that detects specific changes in the glycan structures attached to glycoprotein biomarkers in blood serum. For prostate cancer, the target is prostate-specific antigen (PSA); the test doesn’t just measure PSA levels, but analyzes the sugar molecules on those PSA proteins. The company claims this glycomics approach, in pre-clinical validation for its GIASAY Prostate test, achieved greater than 95% accuracy, with 100% sensitivity and 94% specificity. If those figures hold in broader clinical studies, it would represent a significant step up from the conventional PSA test, which has a specificity often cited below 25% in some screening populations.
The strategic advantage is practical deployment. The tests are designed to run on standard ELISA equipment already ubiquitous in clinical laboratories, positioning them as an affordable, drop-in upgrade rather than a capital-intensive new platform. The intended use is clear: to help physicians decide whether a biopsy is truly necessary for a patient with elevated PSA, or to monitor patients after treatment.
From academic roots to a regulated launch
The company’s foundation is deeply academic. It was co-founded by two Slovak scientists, Jan Tkáč and Tomáš Bertok, both internationally recognized for their work in glycomics and biosensor research. To steer the venture from lab to clinic, they brought in CEO Eva Kovacova in 2021, a financial executive with nearly two decades of experience in European pharmaceutical M&A and licensing [Success.ai, retrieved 2024]. This blend of deep science and industry commercial expertise is a common, if not always successful, recipe for European biotech startups.
Funding, totaling approximately $2.18 million to date, has come from a mix of equity crowdfunding and significant European institutional grants, including support from the European Innovation Council Fund [PitchBook, retrieved 2024]. The capital has supported the development of a pipeline aimed at 11 solid tumor types, with breast cancer (GIASAY Breast) slated to follow prostate. The immediate commercial focus, however, is entirely on the European market. The company plans to obtain a CE mark for its prostate test in 2025, enabling a full commercial launch through laboratory chains in Slovakia, Austria, and Germany [Apple Podcasts, retrieved 2026].
| Founder / Leader | Role | Key Background |
|---|---|---|
| Jan Tkáč | Co-Founder | Internationally renowned scientist specializing in glycomics and biosensors. |
| Tomáš Bertok | Co-Founder | Chemist and biosensor researcher focused on electrochemical and glycan-based diagnostics. |
| Eva Kovacova | CEO | Joined in 2021; 18 years in pharma M&A, licensing, and financial leadership in Europe [Success.ai, retrieved 2024]. |
The risks in the roadmap
For all its scientific promise, Glycanostics’s path is lined with the standard, formidable hurdles of diagnostic medicine. The pre-clinical validation data, while compelling, awaits peer-reviewed publication and confirmation in larger, multi-center clinical trials. Regulatory clearance via the CE mark is a critical near-term milestone, but reimbursement from European health systems is a separate and often protracted battle. The company’s go-to-market strategy relies on partnerships with laboratory chains, a sensible approach that nonetheless transfers some commercial control and requires proving a compelling economic case for labs to adopt the new test.
Competitively, the field of liquid biopsy is crowded with well-funded players focused on circulating tumor DNA (ctDNA). Glycanostics’s glycomics angle is a distinct niche, but it must convince clinicians to look beyond the genomic narrative that currently dominates oncology investment. Furthermore, the company’s ambition to expand to 11 cancer types is a long-term platform bet that will require substantial additional capital and clinical validation for each indication.
The company’s most plausible answer to these challenges is focus. By concentrating its initial resources on obtaining the CE mark and launching the prostate cancer test in a defined European region, it aims to generate early clinical utility data and revenue. This could create a foundation for future pipeline expansion and attract the next round of funding necessary for U.S. FDA trials, a stated longer-term goal.
What to watch in the next 12 months
The coming year is pivotal. The planned CE mark acquisition is the single most important catalyst, unlocking the ability to sell the test commercially. Success will be measured not just by regulatory approval, but by the signing of the first laboratory chain partners in Central Europe and the generation of initial real-world usage data. The company will also need to navigate the transition from grant and crowdfunding support to a more traditional venture round to finance its breast cancer program and further clinical studies.
For men facing an elevated PSA result and the anxiety of a potential biopsy, the standard of care today remains a difficult calculus. The PSA test is a blunt instrument, leading to over-diagnosis and unnecessary invasive procedures for many, while still missing some aggressive cancers. The traditional next step, a tissue biopsy, is painful, carries risks of infection and bleeding, and samples only a small portion of the prostate. Glycanostics is betting that a vial of blood, analyzed for its sugar-coated signals, can provide a clearer, safer answer. The patients waiting for that answer are the ultimate measure of whether this Slovak startup’s scientific wedge can carve out a new space in cancer diagnostics.
Sources
- [PitchBook, retrieved 2024] Glycanostics funding profile | https://www.crunchbase.com/organization/glycanostics
- [Success.ai, retrieved 2024] Eva Kovacova company profile | https://www.success.ai/company-directory/Glycanostics-57485757
- [Apple Podcasts, retrieved 2026] Interview discussing commercial launch plans | https://podcasts.apple.com/us/podcast/interview-%C4%8Dt24/id1774254406